Barclays PLC vs Biogen Inc — how do they compare? Barclays PLC trades at $28 (market cap $93.87B), while Biogen Inc trades at $202.7 (market cap $30.13B). The key difference: Barclays PLC is far larger — about 3.1× Biogen Inc's market cap, and Barclays PLC pays a 2.19% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BCS | BIIB | |
|---|---|---|
Market Cap | $93.87B | $30.13B |
Sector | Financials | Health |
52-Week High | $28.56 | $216.63 |
52-Week Low | $19.36 | $128.93 |
Dividend Yield | 2.19% | — |
Enterprise Value | — | $37.20B |
Trailing returns across standard periods
Latest headlines on both assets
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →